| Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. | breast, |
| Membranous levels of c-erbB-2 oncoprotein in gastric cancer: their relationship with clinicopathological parameters and their prognostic significance. | gastric, |
| HER2/neu increases the expression of Wilms Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. | breast, |
| [Relationship of oncogene C-erbB-2 amplification in breast cancer with pathological parameters and disease free survival]. | breast, |
| Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. | breast, |
| Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. | breast, |
| HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. | sarcoma,uterine, |
| Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. | breast, |
| [Diagnostic and prognostic value of the oncoprotein her-2/neu in the breast cancer tissue]. | breast, |
| HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. | ovarian, |
| Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. | uterine, |
| Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role?. | leukemia,lung, |
| Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma. | sarcoma, |
| Rare occurrence of amplification of HER-2 (erbB-2/neu) oncogene in ovarian cancer patients. | ovarian, |
| C-erbB2 oncoprotein: prognostic marker in breast cancer. | breast, |
| Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens. | breast, |
| Expression of c-erbB-2 oncoprotein and the prognosis of patients with cervical carcinoma. | cervical, |
| Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma. | thyroid, |
| A genomic explanation connecting Mediterranean diet, olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory PEA3 transcription factor-PEA3 DNA binding site complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells. | gastric,breast,ovarian, |
| The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. | ovarian, |